Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.
In-hospital initiation of the PCSK9* inhibitor evolocumab, on top of high-intensity statin therapy, in the very high-risk, acute phase of ACS** significantly reduced LDL-C levels — so much so that >95 percent of the patients achieved the recommended target levels — compared with high-intensity statin alone, the EVOPACS*** study has shown.
The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.
Recently published cardiovascular outcome trials (CVOTs) in patients with diabetes (DM) have led to updates in the management of cardiovascular disease (CVD) in DM patients. These updates were reflected in the 2019 ESC guidelines on diabetes, prediabetes, and CVD, a collaboration between ESC and EASD*.
The once-daily fixed-dose combination of candesartan plus rosuvastatin reduces systolic blood pressure and low-density lipoprotein cholesterol at the same time with no major safety issues, according to the results of a phase III trial. This drug represents a convenient treatment option for patients with coexistent essential hypertension and hypercholesterolaemia.
Use of ezetimibe to manage elevated low-density lipoprotein cholesterol (LDL-C) levels in individuals aged ≥75 years proves beneficial in the primary prevention of coronary artery disease (CAD) events, reducing the risk of a composite of sudden cardiac death, myocardial infarction, coronary revascularization or stroke, according to data from the open-label EWTOPIA* 75 trial.
The three-drug combination of telmisartan, amlodipine and rosuvastatin yields significant reductions in blood pressure and low-density lipoprotein cholesterol levels in patients with hypertension and dyslipidaemia while having a good safety profile and tolerability, according to data from the J-TAROS* trial.
A dietary strategy of carbohydrate restriction proves superior to low-fat diets in terms of improving lipid markers in individuals with cardiometabolic risk, owing to its strong effects on high-density lipoprotein cholesterol and triglycerides, according to a meta-analysis.
Young, healthy individuals at low risk for atherosclerotic cardiovascular disease (ASCVD) events may still face a heightened lifetime risk of death from CV events if they have elevated LDL-C levels of ≥160 mg/dL, reveals the CCLS*.
Lipid-lowering with ezetimibe monotherapy was effective for the primary prevention of atherosclerotic cardiovascular (CV) events in middle- to high-risk elderly Japanese patients with hypercholesterolaemia, according to the EWTOPIA75* study presented at AHA 2018 Scientific Sessions.
A left ventricular ejection fraction (LVEF) cut-off of 60 percent may identify patients with heart failure (HF) with mid-range or preserved ejection fraction (mrEF or pEF) who could benefit from drug therapy.
Target organ damage appears to be more noticeable in patients affected by primary aldosteronism than those affected by arterial hypertension without primary aldosteronism, suggests a study, adding that specific treatment can ease such condition.